Diabetes Diagnosis & Management 2015

San Diego, CA US

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists and endocrine fellows, pediatric endocrinologists and pediatric endocrine fellows, endocrine physician’s assistants and internal medicine physicians who treat diabetes, geriatricians, nurses, and other healthcare professionals who treat patients with diabetes.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

Automating Glycemic Regulation with a Bionic Pancreas

  • Review the components of an artificial pancreas and its mechanisms
  • Review the advantages and disadvantages of artificial pancreas technology in practice
  • Anticipate next steps for the development of artificial pancreas technology
  • Evaluate the efficacy of the artificial pancreas
  • Determine which patients would react beneficially with the artificial pancreas

Is it Type 1 or Type 2: When and How to Screen?

  • Differentially diagnose T1D in youth and assess the familial risk of developing T1D

Cardiovascular in Type 1 Diabetes:  Epidemiology and Prevention                               

  • Evaluate clinical practice guidelines on the prevention, screening and management of comorbidities
  • Identify blood pressure treatment targets and preferred pharmacologic treatment options for patients with diabetes
  • Describe the changing epidemiologic features of CVD risk factors and CVD events in diabetes
  • Compare the effectiveness of established CVD prevention treatments in T1DM and T2DM versus the non-diabetic at-risk population

Glycemic Variability:  Does it Matter?  How to Assess It? And Strategies for Management

  • Describe the importance of managing glycemic variability
  • Recognize the risk factors associated with glucose variability
  • Evaluate the effectiveness of using emerging therapies to manage glycemic variability

Incretins and Insulin in T1 and T2 Diabetes                 

  • Determine the benefits and best treatment options for GLP-1 analogs

Novel Therapy Highlight

  • Review the effectiveness and utility of SGLT2 inhibitors and identify patients who are most appropriate for this class of medicines
  • Review the effectiveness and utility of novel GLP1 agonist, and choose patients who are most appropriate for this class of medicines
  • Describe the novel therapies for T2DM and the clinical impact of each
  • Discuss the benefits and limitations of emerging combination therapies including inhaled insulin as adjunct treatments to meet A1c targets

CGM for the Masses

  • Identify a patient who might benefit from continuous glucose monitoring
  • Recognize common patterns from continuous glucose monitoring reports
  • Counsel patients on the use of data from continuous glucose monitoring
  • Evaluate clinical practice guidelines on diabetes and management of comorbidities and predict how these will evolve in light of new data and clinical experience

Approaches to Reducing Hypoglycemia and Hypoglycemia Unawareness

  • Explain the neurological consequences of hypoglycemia and hyperglycemia and recognize potential causes

Prevention and Management of Diabetic Kidney Disease

  • Identify pharmacologic solutions to delay progression of nephropathy
  • Recognize the adverse outcomes associated with hypoglycemia and ways to prevent hypoglycemic events with particular attention to matching the anti-hyperglycemic regimen to nutritional intake

Diabetic Neuropathy

  • Screen patients for early clinical signs of neuropathy
  • Effectively manage cardiovascular autonomic neuropathy in T2DM patients

Diagnosis and Management of Type 2 Diabetes in Children

  • Differentially diagnose Type 2 diabetes in children
  • Determine the most effect treatment strategies for managing type 2 diabetes in children

In Hospital Glycemic Control

  • Employ appropriate techniques to achieve and maintain normoglycemia in in-patients  
  • Manage physiologic insulin replacement programs based on the individual’s needs
  • Recognize the adverse outcomes associated with hypoglycemia and ways to prevent hypoglycemic events with particular attention to selection of medical therapies and matching the anti-hyperglycemic regimen to nutritional intake
  • Recognize special considerations in the management of diabetes in a trauma or in-patient setting

Overlapping Treatment of Depression and Diabetes

  • Utilize patient education and counseling to motivate patients and their caregivers and promote adherence

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
Systems-based Practice
Topic Area: 
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Health Disparities
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credits
  • 6.00 CME Certificate of Participation
Course opens: 
Course expires: 
San Diego Convention Center
111 West Harbor Drive
San Diego, CA 92101
United States

Program Chairs

Kieren J Mather, MD; Indiana Univ
Carol H Wysham, MD; Rockwood Clin/Univ of Washington Sch of Med


Ashok Balasubramnyan, MD; Baylor College of Med
Timothy Bailey, MD; Univ of California, San Diego Sch of Med
Matthew Budoff, MD; Univ of California, Los Angeles Sch of Med
George Dailey III, MD; Scripps Clinic
Ian De Boer, MD; Univ of Washington Sch of Med
Peter Dyck, MD; Mayo Clinic
Irl Hirsch, MD; Univ of Washington Sch of Med
Kristen Nadeau, MD; Univ of Colorado/Children's Hosp of Colorado
Anne L Peters, MD, CDE; Univ of Southern California
Steven J Russell, MD, PhD; Massachusetts Gen Hosp
Elizabeth Seaquist, MD; Univ of Minnesota
Guillermo Umpierrez, MD; Emory Univ Sch of Med
Jill Weissberg-Benchell, PhD, CDE; Northwestern University Feinberg School of Medicine


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Timothy Bailey, MD: Consultant and Research Funding, Bayer, Inc., BD, Medtronic, Novo Nordisk, Sanofi; Research Funding, Abbott Laboratories, ACON, Alere, Animas, Bayer, Inc., BD, Cebix, Bristol-Myers Squibb, Dexcom, Eli Lilly & Company, GlaxoSmithKline, Halozyme, Insulet, Lifescan, Mannkind, Medtronic, Merck & Co., Novo Nordisk, Orexigen, Sanofi, Tandem

Peter Dyck, MD: Honoraria, American Diabetes Association; Honoraria and Grants, Alnylam, Inc., ISIS, Inc.

Irl Hirsch, MD: Ad Hoc Consultant, Roche Diagnostics, Valeritas; Advisory Group Member, Abbott Laboratories; Principal Investigator, Halozyme, Novo Nordisk, Sanofi

Kieren J Mather, MD: Clinical Researcher, Merck & Co., Novo Nordisk, Sanofi

Anne L Peters, MD, CDE: Advisory Group Member, Abbott Laboratories, Amgen, AstraZeneca Eli Lilly & Company, Jansen Pharmaceuticals, Lexicon Pharmaceuticals, Inc., Medscape, Medtronic Minimed, Novo Nordisk, Sanofi, Takeda; Investigator, Jansen Pharmaceuticals, Medtronic Minimed; Speaker Bureau Member, Bristol-Myers Squibb, Novo Nordisk

Elizabeth Seaquist, MD: Consultant and Investigator, Locemia; Investigator, Eli Lilly & Company; Speaker, Sanofi

Guillermo Umpierrez, MD: Consultant and Investigator, Boehringer Ingelheim, Merck & Co., Novo Nordisk

The following faculty reported no relevant financial relationships: Ashok Balasubramnyan, MD; Matthew Budoff, MD; George Dailey III, MD; Ian De Boer, MD; Kristen Nadeau, MD; Steven J Russell, MD, PhD; Jill Weissberg-Benchell, PhD, CDE; Carol H Wysham, MD

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 6.00 AMA PRA Category 1 Credits
  • 6.00 CME Certificate of Participation